Citations

Clear

1422 citation(s) found for "White, JB".

Summary: international consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes
Michelena, Héctor I. , Evangelista, Arturo , Maleszewski, Joseph J. , Edwards, William D. , Roman, Mary J. , Devereux, Richard B. , Fernández, Borja , Sierra-Galán, Lilia M. , Girdauskas, Evaldas , Delgado, Victoria , Lansac, Emmanuel , Bissell, Malenka M. , Hope, Michael D. , Sitges, Marta , Thourani, Vinod H. , Pibarot, Phillippe, Chandrasekaran, Krishnaswamy , Lancellotti, Patrizio , Forrest, John K. , Webb, John G. , Makkar, Raj , Leon, Martin B. , Markl, Michael , Ferrari, Victor A. , Roberts, William C. , Svensson, Lars G. , Braverman, Alan C. , Bavaria, Joseph E. , Sundt, Thoralf M. , Khoury, Gébrine El , Paulis, Ruggero De , Michelena, Hector I , Delgado, Victoria , Bissell, Malenka M , De Paulis, Ruggero , Enriquez-Sarano, Maurice , Markl, Michael , Ferrari, Victor A , Corte, Alessandro Della , Asch, Federico M. , Barker, Alex J. , De Kerchove, Laurent , Fernandes, Susan M , Fedak, Paul W M , Abbara, Suhny , Prakash, Siddharth K. , Popescu, Bogdan A. , Borger, Michael A. , Milewicz, Dianna M. , Sanders, Stephen Pruett , Song, Jae‐Kwan , Blanke, Philipp , White, Charles S , Siu, Samuel , Enriquez‐Sarano, Maurice , Bax, Jeroen J. , Otto, Catherine M , Schäfers, Hans‐Joachim

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | January 23, 2021 | Volume: 60 | Issue: 3 | Pages: 481-496

10.1093/ejcts/ezab039 | PMID 34292332 Get It

Abstract This International evidence-based nomenclature and classification consensus on the congenital bicuspid aortic valve and its aortopathy recognizes 3 types of bicuspid aortic valve: 1. Fused type, with 3 phenotypes: right-left cusp fusion, right-non cusp fusion and left-non cusp fusion; 2. 2-sinus type with 2 phenotypes: Latero-lateral and antero-posterior; and 3. Partial-fusion or forme fruste. This consensus recognizes 3 bicuspid-aortopathy types: 1. Ascending phenotype; root phenotype; and 3. extended phenotypes.
Improving Access to Self-Expanding Metal Stents for Patients With Esophageal Cancer in Eastern Africa: A Stepwise Implementation Strategy
Mushi, Beatrice P. , Kaimila, Bongani , Mulima, Gift , Kelly, Paul , Akoko, Larry , Selekwa, Msiba , Ringo, Yona, Pritchett, Natalie , White, Russell E., Topazian, Mark , Fleischer, David E., Mwachiro, Michael , Buckle, Geoffrey Colin , Kayamba, Violet J. , Mmbaga, Elia John , Dawsey, Sanford M. , Loon, Katherine Van

Mayo Clinic

JCO Global Oncology | January 15, 2021 | Volume: No volume available | Issue: 7 | Pages: 118-126

10.1200/go.20.00318 | PMID 33449802 Get It

PURPOSE The eastern corridor of Africa is affected by a high burden of esophageal cancer (EC), with > 90% of patients presenting with advanced disease. Self-expanding metal stents (SEMS) have been previously reported as safe and effective for palliation of malignant dysphagia in resource-limited settings; however, access is limited throughout Eastern Africa. METHODS In response to demand for palliative interventions for patients with dysphagia because of EC, the African Esophageal Cancer Consortium (AfrECC) partnered with the Clinton Health Access Initiative to improve access to SEMS in Eastern Africa. We undertook a stepwise implementation approach to (1) identify barriers to SEMS access, (2) conduct a market analysis, (3) select an industry partner, (4) establish regulatory and procurement processes, (5) develop endoscopic training resources, (6) create a medical device registry, and (7) establish principles of accountability. RESULTS Following an evaluation of market demand and potential SEMS manufacturers, Boston Scientific Corporation announced its commitment to launch an access program to provide esophageal SEMS to patients in Tanzania, Kenya, Malawi, and Zambia at a subsidized price. Parallel regulatory and procurement processes were established in each participating country. Endoscopy training courses were designed and conducted, using the Training-of-Trainers model. A device registry was created to centralize data for quality control and to monitor channels of SEMS distribution. Principles of accountability were developed to guide the sustainability of this endeavor. CONCLUSION The AfrECC Stent Access Initiative is an example of a multisector partnership formed to provide an innovative solution to align regional needs with a supply chain for a high-priority medical device.
Favorable Outcomes with Reduced Steroid Use in Juvenile Dermatomyositis
Orandi, Amir B. , Lai, Jamie, Morris, Hallie F. , French, Anthony R. , Baszis, Kevin , Orandi, Amir B , Fotis, Lampros , White, Andrew J.

Mayo Clinic

No container title available | January 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-142233/v1 Get It

Abstract Background High-intensity glucocorticoid regimens are commonly used to induce and maintain remission in Juvenile Dermatomyositis (JDM) but are associated with several adverse side-effects. Eminence-based treatment guidelines from CARRA and SHARE both advocate induction of intravenous pulse steroids followed by high dose oral steroids (2 mg/kg) tapered over 12 months. This study compares the time to disease control with reduced glucocorticoid dosing. Methods We retrospectively reviewed the records at a single tertiary-care children’s hospital of patients with JDM between 2000 and 2014 who had a minimum of 2 years of follow-up. The primary outcome measure was time to control of muscle and skin disease. Additional outcome measures included glucocorticoid dosing, effect of treatment on height, frequency of calcinosis and complications from treatment. Results Of the 69 patients followed during the study period, 31 fulfilled inclusion criteria. Median length of follow-up was 4.58 years, (3–7.5). Myositis control was achieved in a median of 7.1 months (range 0.9–63.4). Cutaneous disease control was achieved in a median of 16.7 months (range 4.3–89.5). The median starting dose of glucocorticoids was 0.85 mg/kg/day, (range 0.5–1.74). The median duration of steroid treatment was 9.1 months, (range 4.7–17.4), while the median duration of any pharmacotherapy was 29.2 months (range 10.4 to 121.3). Sustained disease control off medications was achieved in 21/31 (68%) patients by the end of review. Persistent calcinosis was identified in only one patient (3%). Conclusion Current accepted treatment paradigms for JDM include oral glucocorticoids beginning at 2 mg/kg/d reduced over 12 months; however, our results suggest that treatment using reduced doses and durations with early use of steroid-sparing agents are comparably effective in achieving favorable outcomes in JDM.
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Sidell, Douglas R. , Balakrishnan, Karthik , Best, Simon R. , Zur, Karen B. , Buckingham, Julia C., Alarcón, Alessandro de , Baroody, Fuad M. , Bock, Jonathan M. , Boss, Emily F. , Bower, Charles M. , Clarke, Jeffrey , Clarke, Kevin D., Cocciaglia, Alejandro , Cotton, Robin T., Cuestas, Giselle , Davis, Kara L. , Defagó, Victor, Dikkers, Frederik G. , Dossans, Ines, Guerra, Walter Florez , Fox, Elizabeth , Friedman, Aaron D. , Grant, Nazaneen N. , Hogikyan, Norman D. , Johnson, Kaalan , Johnson, Liane B. , Johnson, Romaine F. , Kelly, Peggy, Klein, Adam M. , Lawlor, Claire M. , Levy, Alejandro G., Licameli, Greg R. , Long, Steve, Manrique, Dayse , McMurray, J. Scott , Meister, Kara D. , Messner, Anna H. , Möhr, Michael , Mortelliti, Anthony J., Novakovic, Daniel , Ongkasuwan, Julina , Piersiala, Krzysztof , Prager, Jeremy D. , Pransky, Seth M. , Raynor, Tiffany , Rodríguez, Hugo, Rodríguez, Verónica P., Scatolini, María Laura , Scheffler, Patrick , Smith, David F. , Smith, Lee P., Smith, Marshall E. , Smith, Richard J. , Sorom, Abraham, Steinberg, Amalia, Stith, John A., Thompson, Dana M. , Thompson, Jerome W. , Varela, Patricio, White, David R. , Wineland, Andre , Yang, Christina J. , Zdanski, Carlton J. , Derkay, Craig S. , Zur, Karen , de Alarcón, Alessandro , Campisi, Paolo , Friedman, Aaron D , Hamdi, Osama , Johnson, Romaine F , Leboulanger, Nicolas , Meister, Kara D , Novakovic, Daniel , Ongkasuwan, Julian , Prager, Jeremy D , Rinkel, Rico N P M , Smith, David F , Wineland, Andre M , Sidell, Douglas R , Davis, Kara L , Balakrishnan, Karthik , Buckingham, Julia, Chen, Sharon , Hamdi, Osama A. , Leboulanger, Nicolas , Lam, Derek J. , Long, Steve, Lott, David G. , Mudd, Pamela A. , Peer, Shazia , Preciado, Diego A. , Russell, John

Mayo Clinic

The Laryngoscope | January 8, 2021 | Volume: 131 | Issue: 6 | Pages: No page available

10.1002/lary.29343 | PMID 33405268 Get It

Objectives/HypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.Study DesignDelphi method‐based survey series.MethodsA multidisciplinary, multi‐institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work‐up.ResultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).ConclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best‐practice applications of systemic bevacizumab for patients with early‐onset or less‐severe disease phenotypes.Level of Evidence5 Laryngoscope, 131:E1941–E1949, 2021
Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization
Takahashi, Kuniaki , Thuijs, Daniel J.F.M. , Gao, Chao , Ono, Masafumi , Holmes, David R. , Mack, Michael J. , Morice, Marie‐Claude, Mohr, Friedrich‐Wilhelm, Curzen, Nick , Davierwala, Piroze , Milojevic, Milan , Dawkins, Keith D., Winter, Robbert J. de , McEvoy, John W. , Onuma, Yoshinobu , Head, Stuart J., Investigators, the SYNTAX Extended Survival Study, de Winter, Robbert J , Serruys, Patrick W , Curzen, Nick , Onuma, Yoshinobu , Milojevic, Milan , Morice, Marie‐Claude, Wykrzykowska, Joanna J. , Kappetein, A. Pieter , Serruys, Patrick W. , Investigators, the SYNTAX Extended Survival Study

Mayo Clinic

European Journal of Preventive Cardiology | January 1, 2021 | Volume: 29 | Issue: 2 | Pages: 312-320

10.1093/eurjpc/zwaa089 | PMID 33624046 Get It

Abstract Aims To evaluate the impact of various smoking status on 10-year all-cause mortality and to examine a relative treatment benefit of coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) according to smoking habits. Methods and results The SYNTAX Extended Survival study evaluated vital status up to 10 years in 1800 patients with de novo three-vessel disease and/or left main coronary artery disease randomized to CABG or PCI in the SYNTAX trial. In the present analysis, patients were divided into three groups (current, former, or never smokers), and the primary endpoint of 10-year all-cause mortality was assessed according to smoking status. Smoking status was available in 1793 (99.6%) patients at the time of randomization, of whom 363 were current smokers, 798 were former smokers, and 632 were never smokers. The crude rates of 10-year all-cause mortality were 29.7% in current smokers, 25.3% in former smokers, and 25.9% in never smokers (Log-rank P = 0.343). After adjustment for imbalances in baseline characteristics, current smokers had a significantly higher risk of 10-year all-cause mortality than never smokers [adjusted hazard ratio (aHR): 2.29; 95% confidence interval (CI): 1.60–3.27; P < 0.001], whereas former smokers did not. PCI was associated with a higher risk of all-cause mortality than CABG among current smokers (HR: 1.60; 95% CI: 1.09–2.35; P = 0.017), but it failed to show a significant interaction between revascularization strategies and smoking status (Pinteraction = 0.910). Conclusion Current smokers had a higher adjusted risk of 10-year all-cause mortality, whereas former smokers did not. The treatment effect of CABG vs. PCI did not differ significantly according to smoking status. Clinical trial registration SYNTAX: ClinicalTrials.gov reference: NCT00114972; SYNTAX Extended Survival. ClinicalTrials.gov reference: NCT03417050.
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy
Walker, Jamie M. , Richardson, Timothy E. , Iida, Megan A., Foong, Chan, Shang, Ping , Attems, Johannes , Ayalon, Gai , Beach, Thomas G. , Bigio, Eileen H. , Budson, Andrew E. , Cairns, Nigel J. , Corrada, María M. , Cortés, Etty , Flanagan, Margaret E. , Franklin, Erin , Gearing, Marla , Glass, Jonathan D. , Hansen, Lawrence A. , Haroutunian, Vahram , Kawas, Claudia H. , Keene, C. Dirk , Kofler, Julia , Kovács, Gábor G. , Lee, Edward B. , Lutz, Mirjam I. , Masliah, Eliezer , McKee, Ann C. , Mesulam, M.‐Marsel, Nelson, Peter T. , Perrin, Richard J. , Pham, Thao, Purohit, Dushyant P. , Sakai, Kenji , Sano, Mary , Stein, Thor D. , Teich, Andrew F. , Trojanowski, John Q. , Troncoso, Juan C. , Vonsattel, Jean-Paul G., Weıntraub, Sandra , Woltjer, Randall L. , Yamada, Masahito , Yu, Lei , Crary, John F. , Seshadri, Sudha , Murray, Melissa, Seshadri, Sudha , Kovacs, Gabor G , Murray, Melissa E , Teich, Andrew F , Lee, Edward B , Farrell, Kurt , Dickson, Dennis W. , Fischer, Peter A. , Hof, Patrick R. , Honig, Lawrence S. , Mao, Qinwen , McMillan, Corey T. , Murray, Melissa E. , Poon, Wayne W. , Rissman, Robert A. , Schneider, Julie A. , Wolk, David A. , White, Charles L. , Flanagan, Margaret E

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 23, 2020 | Volume: 80 | Issue: 2 | Pages: 102-111

10.1093/jnen/nlaa153 | PMID 33367843 Get It

Abstract Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-β (Aβ) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aβ pathology in AD and PART.
Transarterial Embolization of a Transverse Sinus Dural Arteriovenous Fistula: 2-Dimensional Operative Video
Gomez‐Paz, Santiago , Akamatsu, Yosuke , Salem, Mohamed M. , Ogilvy, Christopher S. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael R. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Ringer, Andrew J. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Levitt, Michael R , Gomez-Paz, Santiago , Schirmer, Clemens M , Ogilvy, Christopher S , Moore, Justin M. , Thomas, Ajith J , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | December 14, 2020 | Volume: 20 | Issue: 1 | Pages: E41-E42

10.1093/ons/opaa370 | PMID 33316817 Get It

Abstract A 40-yr-old male with no significant past medical history presented with sudden onset right-sided retro-orbital headache associated with vision loss after a session of strenuous exercise. Initial assessment with noncontrast head computed tomography at the local emergency department revealed a right sided occipital intracranial hemorrhage (ICH). On arrival the patient ad a left quadrantopsia with Glasgow Coma Scale of 15 and an ICH score of 0. A computed tomographic angiography showed a high density 6 × 9 mm vascular lesion associated with 2 tortuous vessels. Cerebral angiography revealed a right sided dural arteriovenous fistula, Cognard Type IV, with arterial feeders arising from dural branches of the right vertebral artery, the posterior division of the right middle meningeal artery and meningeal branches distal to the neuromeningeal trunk of the left ascending pharyngeal artery. 1 Four days after the ICH event the patient was treated with endovascular Onyx embolization of the fistula, through a transradial approach. Immediate angiographic assessment showed complete obliteration of the dAVF. The patient was discharged home and recovered his visual field deficit over 3 mo. The following operative video includes a discussion of the endovascular technique and treatment nuances associated with the transarterial management of a dural arteriovenous fistula. Patient consent was given prior to the procedure and consent and approval for this operative video was waived due to the retrospective nature of this manuscript and the anonymized video material.
Distal Access to Wide-Necked Aneurysms—‘Around the World’ Technique: 2-Dimensional Operative Video
Ringer, Andrew J. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael R. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Ogilvy, Christopher S. , Levitt, Michael R , Schirmer, Clemens M , Ogilvy, Christopher S , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | December 14, 2020 | Volume: 20 | Issue: 1 | Pages: E39-E40

10.1093/ons/opaa369 | PMID 33316816 Get It

Abstract Wide-necked aneurysms often pose challenges for distal access to the distal vasculature. This 64-yr-old woman without neurological deficits presented with atypical headaches of gradual onset. MRI revealed a large, symptomatic, unruptured carotid terminus aneurysm incorporating the origin of both the middle (MCA) and anterior cerebral arteries (ACA). Its wide neck created significant risks to coil prolapse and parent vessel compromise, risking stroke. With other options of higher risks, we recommended an around-the-world technique. Standard transfemoral access was used to the right internal carotid artery (ICA) with a 6F-Shuttle sheath and intracranial carotid with a 6F-Sofia distal access catheter. With dual-microcatheter access, 1 catheter was placed in the aneurysm dome, a second in the MCA for stent placement. Advancing the wire around the aneurysm first formed a loop from the lateral to medial wall for access to the MCA. The microcatheter was then advanced around the wire into the MCA, keeping the loop within the dome. With the loop's distal tip anchored, the distal end of the stent was deployed and anchored into the MCA. Both pitfalls (ie, lack of sufficient distal access, collapse of stent device during deployment) were resolved using a balloon catheter. With the balloon positioned and inflated as the anchor, the wire and catheter were pulled together. The loop in the aneurysm's dome straightened out across the neck, the stent was advanced into the MCA, and coiling proceeded. A large neck remnant had partially closed on 6-mo follow-up angiogram. Patient consented to undergo the procedure. Illustrations in video published/printed with permission from Mayfield Clinic.
Stent-Assisted Coiling of a Sidewall Aneurysm of the Distal Middle Cerebral Artery: 2-Dimensional Operative Video
Cavalcanti, Daniel D. , Delavari, Nader , Riina, Howard A. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levy, Elad, Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, E, Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | December 14, 2020 | Volume: 20 | Issue: 1 | Pages: E37-E38

10.1093/ons/opaa332 | PMID 33316814 Get It

Abstract Sidewall aneurysm treatment often requires complex management strategies. These can include advanced clipping techniques or stent-assisted coiling techniques. Endovascular coiling alone has been associated with high recurrence rates and is often not feasible. 1-4 Flow-diversion embolization has recently become a standard of care for many aneurysms, demonstrating high occlusion rates. 4,5 However, the third generation of coil-assist stents can be delivered with 0.0165” microcatheters, being an ideal adjunct to manage this group of aneurysms in more distal locations. In this video, a 16-yr-old teenager with Parry-Romberg syndrome and congenital adrenal hyperplasia had an incidental finding of a 6.5-mm sidewall aneurysm arising off the angular branch of the left middle cerebral artery, found during the work-up of complex partial seizures. The patient consented to the procedure. Due to his young age and aneurysm size, a decision was made to treat the aneurysm through an endovascular approach. Under general anesthesia, a transfemoral approach was carried out using a 6-French short sheath. A 6-French guiding catheter was left in the distal cervical left internal carotid artery; a 0.0165” microcatheter was used to first deploy a 3.0 × 15 mm Neuroform Atlas stent, completely covering the length of the aneurysm. Then, the stent was traversed with the microcatheter to coil the aneurysm. Follow-up cerebral angiogram confirmed complete occlusion of the aneurysm.
Refractory rhabdomyolysis responsive to corticosteroid therapy
Hammers, Marissa, Hashim, Faris , Hanna, Christian , Farris, Amanda C., Blasick, Stephanie , Hanna, Christian , Hammers, Marissa J

Mayo Clinic

Baylor University Medical Center Proceedings | December 14, 2020 | Volume: 34 | Issue: 2 | Pages: 314-315

10.1080/08998280.2020.1851627 | PMID 33678976 Get It